Evidence map›Paper›PMID 39190234›Full record

ArticleMetabolic brain disease2024

Involvement of oncomiRs miR-23, miR-24, and miR-27 in the regulation of alternative polyadenylation in glioblastoma via CFIm25 cleavage factor.

Mozhgan Foroutan Kahangi, Vahid Tavakolpour, Iman Samiei Mosleh, Saeed Oraee-Yazdani, Fatemeh Kouhkan

Abstract read
PubMed Publisher
In one paragraph

Article in Metabolic brain disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mozhgan Foroutan KahangiStem Cell Technology Research Center (STRC), Iran University of Medical Sciences (IUMS), Tehran, Iran.ORCID 0000-0001-7512-0670
Vahid TavakolpourStem Cell Technology Research Center (STRC), Iran University of Medical Sciences (IUMS), Tehran, Iran.ORCID 0000-0002-8785-6084
Iman Samiei MoslehPlant Functional Genomics Lab, Institute of Molecular Biotechnology, Department of Biotechnology, BOKU University, Vienna, Austria.ORCID 0000-0002-0149-0991
Saeed Oraee-YazdaniFunctional Neurosurgery Research Center, Shohada Tajrish Comprehensive Neurosurgical Center of Excellence, Shahid Beheshti University of Medical Sciences, Tehran, Iran.ORCID 0000-0003-4550-9698
Fatemeh KouhkanStem Cell Technology Research Center (STRC), Iran University of Medical Sciences (IUMS), Tehran, Iran. f.kouhkan@yahoo.com.ORCID 0000-0001-7262-0207

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma multiforme (GBM) is a highly aggressive brain tumor with a poor prognosis. The cleavage factor Im 25 (CFIm25), a crucial component of the CFIm complex, plays a key role in regulating the length of the mRNA 3'-UTR and has been implicated in various cancers, including GBM. This study sought to investigate the regulatory influence of specific microRNAs (miRNAs) on CFIm25 expression in GBM, a highly aggressive brain tumor. Bioinformatics analysis identified miRNA candidates targeting CFIm25 mRNA, and gene expression profiles from the NCBI database (GSE90603) were used for further analysis. Expression levels of CFIm25 and selected miRNAs were assessed using qRT-PCR in GBM clinical samples (n = 20) and non-malignant brain tissues (n = 5). Additionally, the MTT assay was performed to examine the effect of miRNA overexpression on U251 cell viability. Lentivectors expressing the identified miRNAs were employed to experimentally validate their regulatory role on CFIm25 in U251 cell lines, and Western blot analysis was conducted to determine CFIm25 protein levels. We observed significantly increased levels of miR-23, miR-24, and miR-27 expression, associated with a marked reduction in CFIm25 expression in GBM samples compared to non-malignant brain tissues. In particular, overexpression of miR-23, miR-24, and miR-27 in U251 cells resulted in CFIm25 downregulation at both the mRNA and protein levels, while their inhibition increased CFIm25 and reduced cell proliferation. These observations strongly implicate miR-23, miR-24, and miR-27 in regulating CFIm25 expression in GBM, emphasizing their potential as promising therapeutic targets for enhancing treatment responses in glioblastoma.

Indexed as

Brain NeoplasmsGene Expression Regulation, NeoplasticGlioblastomaMicroRNAsPolyadenylationCell Line, TumorCell ProliferationCleavage And Polyadenylation Specificity FactorFemaleHumansMaleMiddle AgedCleavage And Polyadenylation Specificity FactorMicroRNAsMIRN224 microRNA, humanMIRN23b microRNA, humanMIRN24 microRNA, humanMIRN27 microRNA, humanNudt21 protein, humanAlternative polyadenylationCFIm25GlioblastomamicroRNAmiR-23miR-24miR-27oncomiR

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.